Switch to:
More From Other Websites
Januvia and Janumet: Merck & Co.’s Blockbuster Diabetes Products Feb 23 2017
Keytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug Feb 22 2017
Merck & Co.’s Segment-Wise Revenues for 4Q16 Feb 22 2017
Analyst: Buy AstraZeneca On The Turnaround Story Feb 22 2017
$250M deal: AstraZeneca sells rights to cancer therapy Feb 21 2017
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan,... Feb 21 2017
Sanofi’s Unique Foothold in Diabetes and Cardiovascular Feb 20 2017
AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink Feb 17 2017
Clovis, Tesaro Soar on Astrazeneca Phase Three News Feb 17 2017
FTSE gains for third week as Unilever rises, Coca Cola HBC sets record Feb 17 2017
European Benchmarks Fall, But London Bucks Trend on Takeover Activity Feb 17 2017
[$$] AstraZeneca boosted by positive breast cancer trial Feb 17 2017
AstraZeneca's Lynparza meets main goal in breast cancer study Feb 17 2017
AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial Feb 17 2017
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ Feb 17 2017
LYNPARZA™ (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast... Feb 17 2017
Britain's FTSE set for week of modest gains, pharmas lead Feb 17 2017
Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook Feb 17 2017
Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook Feb 16 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK